Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Rating of "Hold" from Brokerages

Moderna, Inc. (NASDAQ:MRNA - Get Free Report) has earned an average recommendation of "Hold" from the twenty-one analysts that are covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and five have issued a buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $86.33.

Several equities analysts have recently issued reports on MRNA shares. Jefferies Financial Group decreased their price target on shares of Moderna from $65.00 to $55.00 and set a "hold" rating for the company in a report on Tuesday, October 15th. The Goldman Sachs Group reduced their price objective on shares of Moderna from $178.00 to $139.00 and set a "buy" rating for the company in a research note on Monday, September 16th. Wolfe Research began coverage on shares of Moderna in a report on Friday. They issued an "underperform" rating and a $40.00 target price on the stock. Needham & Company LLC reaffirmed a "hold" rating on shares of Moderna in a report on Friday, November 8th. Finally, Barclays dropped their target price on shares of Moderna from $125.00 to $111.00 and set an "overweight" rating on the stock in a report on Friday, November 8th.

Moderna Trading Up 5.9 %

MRNA stock traded up $2.19 during trading on Monday, hitting $39.04. The company had a trading volume of 9,356,046 shares, compared to its average volume of 4,731,261. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The firm has a 50-day moving average price of $58.56 and a 200-day moving average price of $96.68. Moderna has a 12 month low of $35.80 and a 12 month high of $170.47. The stock has a market cap of $15.02 billion, a price-to-earnings ratio of -6.70 and a beta of 1.69.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. During the same quarter in the previous year, the business earned ($1.39) EPS. The firm's revenue was up 3.8% on a year-over-year basis. As a group, analysts predict that Moderna will post -9.43 earnings per share for the current year.

Insider Activity

In related news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares of the company's stock, valued at $571,440.60. This trade represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders sold 2,930 shares of company stock valued at $217,170. Insiders own 15.70% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in MRNA. Commerzbank Aktiengesellschaft FI grew its position in shares of Moderna by 1.7% during the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company's stock valued at $660,000 after acquiring an additional 93 shares during the period. CVA Family Office LLC grew its holdings in Moderna by 21.6% in the 2nd quarter. CVA Family Office LLC now owns 541 shares of the company's stock worth $64,000 after acquiring an additional 96 shares during the last quarter. Claro Advisors LLC boosted its stake in shares of Moderna by 2.0% during the 2nd quarter. Claro Advisors LLC now owns 5,546 shares of the company's stock valued at $659,000 after purchasing an additional 108 shares in the last quarter. McAdam LLC boosted its stake in shares of Moderna by 1.1% during the 2nd quarter. McAdam LLC now owns 11,075 shares of the company's stock valued at $1,315,000 after purchasing an additional 117 shares in the last quarter. Finally, 180 Wealth Advisors LLC boosted its stake in Moderna by 1.1% during the second quarter. 180 Wealth Advisors LLC now owns 14,868 shares of the company's stock worth $1,826,000 after acquiring an additional 160 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.